

Micro-X Limited, ABN 21 153 273 735

DRX REVOLUTION NANO INSTALLED AT THE ALFRED HOSPITAL MELBOURNE

First Clinical use of Nano in Australia – Assessment prior to purchase

Adelaide, Australia, 25th November 2019: Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a leader in cold cathode X-ray technology for health and security markets globally, is pleased to report that the Company's *DRX Revolution Nano* for mobile medical X-ray, has now been installed and commissioned at The Alfred Hospital in Melbourne, Australia which will become the first centre in Australia to use the Nano in clinical diagnostic imaging.

The installation followed the recent entry of the *DRX Revolution Nano* on the Australian Register of Therapeutic Goods (ARTG), the regulatory requirement for the product to be used clinically or commercially sold in Australia. Micro-X staff have completed commissioning of the Nano unit, the world's first Carbon Nanotube powered X-ray imager, in the Radiology Department of The Alfred Hospital in Melbourne, one of Australia's leading teaching and trauma hospitals.

The Alfred will undertake a three month operational assessment of the unit prior to a purchasing decision, which is expected to involve use of the Nano in various clinical settings including in The Alfred Emergency and Trauma Centre and the hospital's recently enlarged Intensive Care Unit. This installation follows on from a long collaboration between The Alfred's Radiology Department and its staff with Micro-X from the earliest stages of the Nano's design and development. This collaboration helped shape the unit's ergonomic design and deliver the desired improvements in mobile X-ray useability and enhancements in operational practices which optimise radiology workflow.

Gillian Tickall, Chief Radiographer at The Alfred Hospital commented: "We are committed to looking at innovations that result in better care and outcomes for our patients. A light mobile X-ray unit provides huge potential benefits in improved patient care and reducing risks for both patients and users. We are looking forward to using the unit clinically."

Micro-X Managing Director, Peter Rowland said: "The DRX Revolution Nano is operational in ten countries around the world and with this milestone, Australia, our local market, will become the eleventh country. We are all very proud to have our revolutionary X-ray product now operating in an Australian hospital and being used to help Australian patients. We have received expressions of interest to procure the Nano from a number of Australian Hospitals and we are working with Carestream's newly appointed Australian distributor, Quantum Health Group (ASX:QTM), to ramp local sales of the Nano in the near term."

- ENDS -

About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube emitter technology. The electronic control of emitters with this technology enables X-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. The Company has its core R&D, engineering and production capability at its facility in Adelaide, Australia.



The Company's first product, the *Carestream DRX Revolution Nano*, is an ultra-lightweight digital medical x-ray system for the rapidly expanding mobile x-ray market in hospitals and healthcare. The *Carestream DRX Revolution Nano* holds 510(k) and CE Mark certifications and is sold commercially in a number of global markets by the Company's exclusive distributor, Carestream Health, Inc.. The Company has a portfolio of innovative products in development, aimed at customer solutions where there is little or no competition. This includes the Mobile Backscatter Imager or MBI which will image Improvised Explosive Devices for security, defence and counter-terrorism applications. The MBI is being jointly developed in partnership with Thales, a global supplier of defence and security technology systems, who are providing technical support and \$10 million of funding.

CONTACTS

Micro-X Limited	Investor Enquiries
Peter Rowland	David Allen / John Granger
Managing Director	Hawkesbury Partners
Tel: +61 8 7099 3966 E: <u>admin@micro-x.com</u>	Tel: +61 2 9103 9494
	E: dallen@hawkesburypartners.com